Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

NCT02794857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: NP001
DRUG: Placebo

Sponsor

Neuraltus Pharmaceuticals, Inc.